Option chain shows key data for IN8bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for IN8bio.

IN8bio (NASDAQ:INAB) Stock, Option Chain

IN8bio

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Wall-Street-ai7-1

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

JCSE

SGMO

Dow Falls Over 150 Points; General Motors Tops Q3 Views

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

ADXN

ATNI

BIVI

BOOM

IRTC

KSCP

MEDP

MKTW

NTBL

SNSE

TCBP

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

movers image

ALTM

AMBO

CTCX

ICCT

LDTC

MLEC

NMHI

OTRK

PALT

PLBY

RMCO

TIGR

Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

IN8bio Inc

INABA DENKISANGYO CO LTD by Inaba Denkisangyo Co., Ltd.

Inaba Denkisangyo Co Ltd

INABA SEISAKUSHO CO LTD by INABA SEISAKUSHO CO LTD.

Inaba Seisakusho Co Ltd

Inabata & Co Ltd

<p>Hilltop Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTH#NYSE">HTH</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.28 by 96.43 percent. This is a 25 percent increase over earnings of $0.44 per share from the same period last year.</p>


Earnings

Earnings Beats

Hilltop Hldgs Q4 2024 GAAP EPS $0.55 Beats $0.28 Estimate

<p>JP Morgan  analyst Brian Essex   maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Neutral and raises the price target from $233 to $244.</p>


Price Target

Analyst Ratings

JP Morgan Maintains Neutral on IBM, Raises Price Target to $244

<p><strong>Atlassian Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) reported financial results for the fiscal second quarter after the market close on Thursday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/25/01/b43352428/atlassian-announces-second-quarter-fiscal-year-2025-results">key details from the print</a>.</p>
<p><strong>Q2 Earnings:</strong> Atlassian reported second-quarter revenue of $1.29 billion, beating <a href="https://www.benzinga.com/calendars/earnings">analyst estimates</a> of $1.24 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 76 cents per share.</p>
<p>Total revenue was up 21% year-over-year, while subscription revenue grew 30% year-over-year. Cash flow from operations came in at&nbsp;$352 million&nbsp;and free cash flow totaled&nbsp;$343 million&nbsp;in the&nbsp;second quarter.</p>
<p>Atlassian ended the quarter with $2.5 billion in cash, cash equivalents and marketable securities.</p>
<p>&#8220;The Atlassian System of Work is resonating with enterprises all over the globe, as business leaders increasingly turn to the Atlassian platform to help teams across their organization collaborate on the opportunities and challenges they face,&#8221; said <strong>Mike Cannon-Brookes</strong>, co-founder and CEO of Atlassian.</p>
<p>&#8220;By infusing AI throughout our world-class cloud platform, we&#8217;re empowering all teams to accelerate collaboration and unlock organizational knowledge, further enabling them to unleash their full potential.&#8221;</p>
<p><strong>Guidance:</strong>&nbsp;Atlassian expects third-quarter revenue to be in the range of $1.345 billion to $1.353 billion. Cloud revenue is expected to grow 23.5% in the third quarter, data center revenue is expected to grow 7% and marketplace and other revenue is expected to be approximately flat.</p>
<p>The company also raised its fiscal year 2025 revenue growth expectations to a range of 18.5% to 19%, up from a range of 16.5% to 17% at the end of the company&#8217;s fiscal first quarter. </p>
<p>Management will further discuss the quarter on a conference call with analysts and investors at 5 p.m. ET.</p>
<p><strong>TEAM Price Action:</strong> <a href="http://benzinga.com/quote/team" target="_blank" rel="noreferrer noopener">Atlassian shares</a> were up 16.13% after hours, trading at $310 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><strong>Check This Out: </strong><br />     • <strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43348280/amazon-ai-powered-aws-boom-can-it-outshine-microsoft-azure">Amazon AI-Powered AWS Boom: Can It Outshine Microsoft Azure?</a></strong></p>
<p><em>Photo: Shutterstock.</em></p>


TEAM

Atlassian Q2 Earnings: Revenue Beat, EPS Beat, Strong Guidance, 'Infusing' AI And More

<p>The Q4 earnings report for <strong>First Business Finl Servs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) was released on Thursday, January 30, 2025 at 04:00 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>First Business Finl Servs beat estimated earnings by 13.0%, reporting an EPS of $1.43 versus an estimate of $1.26.</p>
<p>Revenue was up $4.52 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.05, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at First Business Finl Servs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.19</td>
<td>1.09</td>
<td>1.12</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.24</td>
<td>1.23</td>
<td>1.04</td>
<td>1.15</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>38.77M</td>
<td>37.25M</td>
<td>37.73M</td>
<td>37.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>38.07M</td>
<td>37.97M</td>
<td>36.28M</td>
<td>36.63M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for First Business Finl Servs <a href="https://www.benzinga.com/quote/FBIZ/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FBIZ

First Business Finl Servs Earnings Report: Q4 Overview

<p><strong>Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.</p>
<p>Revenue was up $2.14 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company missed on EPS by $0.08 in the previous quarter, leading to a 14.000000000000002% drop share price change the next day.</p>
<p>Here's a look at Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.</p>
<p>To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TBBK

Bancorp: Q4 Earnings Insights

<p><strong>Standex International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) just disclosed its Q2 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.</p>
<p>Revenue was up $11.41 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 4.0% increase share price change the next day.</p>
<p>Here's a look at Standex International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Standex International Q2 Earnings

<p>The Q4 earnings report for <strong>Weyerhaeuser</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) was released on Thursday, January 30, 2025 at 04:11 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Weyerhaeuser beat estimated earnings by 56.99999999999999%, reporting an EPS of $0.11 versus an estimate of $0.07.</p>
<p>Revenue was down $66.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.04, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at Weyerhaeuser's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.01</td>
<td>0.21</td>
<td>0.15</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.05</td>
<td>0.21</td>
<td>0.16</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.68B</td>
<td>1.95B</td>
<td>1.85B</td>
<td>1.86B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.68B</td>
<td>1.94B</td>
<td>1.80B</td>
<td>1.77B</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Weyerhaeuser <a href="https://www.benzinga.com/quote/WY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Weyerhaeuser Q4 Earnings Assessment

<p><strong>Canadian National Railway</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Canadian National Railway missed estimated earnings by -3.0%, reporting an EPS of $1.3 versus an estimate of $1.34.</p>
<p>Revenue was down $169.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Canadian National Railway's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.23</td>
<td>1.41</td>
<td>1.25</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.26</td>
<td>1.35</td>
<td>1.28</td>
<td>1.48</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.98B</td>
<td>3.21B</td>
<td>3.10B</td>
<td>3.23B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.01B</td>
<td>3.16B</td>
<td>3.15B</td>
<td>3.29B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Canadian National Railway management provided guidance for FY 2025, expecting earnings between $5.58 and $5.84 per share.</p>
<p>To track all earnings releases for Canadian National Railway <a href="https://www.benzinga.com/quote/CNI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Canadian National Railway Earnings Report: Q4 Overview

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Eastman Chemical Q4

<p>The Q2 earnings report for <strong>Viavi Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) was released on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Viavi Solutions beat estimated earnings by 30.0%, reporting an EPS of $0.13 versus an estimate of $0.1.</p>
<p>Revenue was up $16.30 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company missed on EPS by $0.0 in the previous quarter, leading to a 7.000000000000001% increase share price change the next day.</p>
<p>Here's a look at Viavi Solutions's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>0.07</td>
<td>0.07</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.06</td>
<td>0.08</td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>240.10M</td>
<td>250.82M</td>
<td>249.08M</td>
<td>251.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>238.20M</td>
<td>252.00M</td>
<td>246.00M</td>
<td>254.50M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Viavi Solutions management provided guidance for Q3 2025, expecting earnings between $0.1 and $0.13 per share.</p>
<p>To track all earnings releases for Viavi Solutions <a href="https://www.benzinga.com/quote/VIAV/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VIAV

Viavi Solutions Earnings Analysis: Q2 Recap

<p><strong>Arthur J. Gallagher</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Arthur J. Gallagher beat estimated earnings by 5.0%, reporting an EPS of $2.13 versus an estimate of $2.03.</p>
<p>Revenue was up $284.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company missed on EPS by $0.01 which was followed by a 2.0% drop in the share price the next day.</p>
<p>Here's a look at Arthur J. Gallagher's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.27</td>
<td>2.24</td>
<td>3.41</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.26</td>
<td>3.49</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.78B</td>
<td>2.76B</td>
<td>3.18B</td>
<td>2.36B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.81B</td>
<td>2.77B</td>
<td>3.26B</td>
<td>2.43B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Arthur J. Gallagher <a href="https://www.benzinga.com/quote/AJG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Arthur J. Gallagher Q4

<p><strong>Adtalem Glb Education</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) reported its Q2 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Adtalem Glb Education beat estimated earnings by 32.0%, reporting an EPS of $1.81 versus an estimate of $1.37.</p>
<p>Revenue was up $54.49 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company beat on EPS by $0.16 in the last quarter, resulting in a 10.0% increase share price change the following day.</p>
<p>Here's a look at Adtalem Glb Education's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.13</td>
<td>1.28</td>
<td>1.16</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.37</td>
<td>1.50</td>
<td>1.23</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>397.70M</td>
<td>398.63M</td>
<td>391.70M</td>
<td>372.79M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>417.40M</td>
<td>409.91M</td>
<td>412.66M</td>
<td>393.24M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Adtalem Glb Education management provided guidance for FY 2025, expecting earnings between $6.1 and $6.3 per share.</p>
<p>To track all earnings releases for Adtalem Glb Education <a href="https://www.benzinga.com/quote/ATGE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Adtalem Global Education Inc. Common Stock

ATGE

Recap: Adtalem Glb Education Q2 Earnings

<p>The earnings results for <strong>United States Steel</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:17 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>United States Steel missed estimated earnings by 0.0%, reporting an EPS of $-0.13 versus an estimate of $-0.13.</p>
<p>Revenue was down $635.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company beat on EPS by $0.09, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at United States Steel's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.47</td>
<td>0.77</td>
<td>0.82</td>
<td>0.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.56</td>
<td>0.84</td>
<td>0.82</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.77B</td>
<td>4.02B</td>
<td>4.21B</td>
<td>3.76B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.85B</td>
<td>4.12B</td>
<td>4.16B</td>
<td>4.14B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for United States Steel <a href="https://www.benzinga.com/quote/X/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


United States Steel Q4 Earnings Assessment

<p>The Q3 earnings report for <strong>Boot Barn Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) was released on Thursday, January 30, 2025 at 04:10 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Boot Barn Holdings beat estimated earnings by 2.0%, reporting an EPS of $2.43 versus an estimate of $2.38.</p>
<p>Revenue was up $87.77 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company missed on EPS by $0.0 in the previous quarter, leading to a 20.0% drop share price change the next day.</p>
<p>Here's a look at Boot Barn Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.95</td>
<td>1.02</td>
<td>0.88</td>
<td>1.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.95</td>
<td>1.26</td>
<td>0.91</td>
<td>1.81</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>423.30M</td>
<td>411.38M</td>
<td>384.89M</td>
<td>521.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>425.80M</td>
<td>423.39M</td>
<td>388.46M</td>
<td>520.40M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Boot Barn Holdings management provided guidance for FY 2025, expecting earnings between $5.81 and $5.9 per share.</p>
<p>To track all earnings releases for Boot Barn Holdings <a href="https://www.benzinga.com/quote/BOOT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BOOT

Boot Barn Holdings Earnings Review: Q3 Summary

<p>Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 20 years by 6.82% on an annualized basis producing an average annual return of 15.24%. Currently, Union Pacific has a market capitalization of $151.52 billion. </p>
<p><strong>Buying $1000 In UNP:</strong> If an investor had bought $1000 of UNP stock 20 years ago, it would be worth <strong>$16,943.73</strong> today based on a price of $249.92 for UNP at the time of writing.</p>
<h3>Union Pacific's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738273510_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<p><strong>PennyMac Mortgage IT</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>PennyMac Mortgage IT beat estimated earnings by 11.0%, reporting an EPS of $0.41 versus an estimate of $0.37.</p>
<p>Revenue was up $23.15 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 1.0% drop in the share price the next day.</p>
<p>Here's a look at PennyMac Mortgage IT's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.35</td>
<td>0.32</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.17</td>
<td>0.39</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>90.91M</td>
<td>91.21M</td>
<td>85.37M</td>
<td>97.10M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>80.86M</td>
<td>71.20M</td>
<td>74.20M</td>
<td>84.77M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for PennyMac Mortgage IT <a href="https://www.benzinga.com/quote/PMT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PennyMac Mortgage IT Earnings Analysis: Q4 Recap

<p>Later adapted as a film, &#8220;The Big Short,&#8221; <strong>Michael Lewis</strong>&#8216; seminal book about the hedge funds that shorted the U.S. housing market before its eventual crash in 2008, shot several Wall Street pros to stardom. Among them were <strong>Porter Collins</strong>, <strong>Steve Eisman</strong>, <strong>Vincent Daniel</strong> and <strong>Danny Moses</strong>, who shorted mortgage-backed debt at FrontPoint Partners.</p>
<p>While the four made a killing from a short position in 2008, the Big Short alums are now focused more on going long. The traders reunited this week at an alternative investments conference in Miami, <a href="https://www.bloomberg.com/news/articles/2025-01-30/-big-short-traders-reuniting-for-hedge-fund-week-are-going-long">according</a> to Bloomberg.</p>
<p>Collins, co-founder of <strong>Seawolf Capital LLC</strong>, said on the panel that he has continued his spirit of contrarianism by investing in Asian markets, where valuations are currently cheaper. Daniel holds similar sentiments, but his rationale is the expectation that the U.S. Dollar will weaken, which would benefit foreign assets.</p>
<p><strong>Michael Burry</strong>, the founder of the hedge fund Scion Capital, was also featured prominently in the book and portrayed by <strong>Christian Bale</strong> in the film. Burry has also been bullish on China for several quarters — per his latest 13f filing, Scion Capital&#8217;s largest position is <strong>Alibaba Group Holding Ltd &#8211; ADR </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>).</p>
<p>The <strong>iShares MSCI China ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) tracks Chinese equities, which have traded cheaper than U.S. stocks for several years.</p>
<p>Moses is also looking at value in the market. The frequent CNBC guest likes gold, as reflected in the <strong>SPDR Gold Trust </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).</p>
<p>Eisman, a University of Pennsylvania alum, touted homebuilder stocks given the shortage of new homes in the U.S. and anticipated easing of Federal Reserve monetary policy.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43350879/sam-bankman-frieds-parents-seek-presidential-pardon-from-trump">Sam Bankman-Fried&#8217;s Parents Seek Presidential Pardon From Donald Trump</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Asia

Global

BABA

MCHI

'The Big Short' Goes Long: Men Who Predicted Housing Bubble Prefer Asian Stocks, Gold

<p>PennyMac Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.36 by 13.89 percent. This is a 6.82 percent decrease over earnings of $0.44 per share from the same period last year.  The company reported quarterly sales of $107.93 million which beat the analyst consensus estimate of $93.95 million by 14.88 percent.  This is a 27.31 percent increase over sales of $84.77 million the same period last year.</p>


PennyMac Mortgage Q4 2024 GAAP  EPS $0.41 Beats $0.36 Estimate, Sales $107.93M Beat $93.95M Estimate

<p>Jefferies  analyst Simon Thackray   assumes James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) from Hold to Buy.</p>


Initiation

Jefferies Assumes James Hardie Industries to Buy

<p><strong>Olin</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Olin beat estimated earnings by 325.0%, reporting an EPS of $0.09 versus an estimate of $-0.04.</p>
<p>Revenue was up $56.40 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.25, leading to a 8.0% drop share price change the next day.</p>
<p>Here's a look at Olin's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.04</td>
<td>0.70</td>
<td>0.38</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>0.62</td>
<td>0.40</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.57B</td>
<td>1.71B</td>
<td>1.65B</td>
<td>1.52B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.59B</td>
<td>1.64B</td>
<td>1.64B</td>
<td>1.61B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Olin <a href="https://www.benzinga.com/quote/OLN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Olin Q4 Earnings

Press Releases

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio Announces Pricing of $12.4 Million Private Placement

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

Health Care

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Comments

IN8bio

IN8bio (INAB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga